FDA Clears Path For Genta’s Genasense In Chronic Lymphocytic Leukemia
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency acknowledges complete response as an appropriate primary endpoint for study; needs confirmatory evidence.
You may also be interested in...
Time To Call It Quits: Genasense Failure Marks Its End And Leaves Genta On The Ropes Again
Genta ended a decade-long effort to validate the effectiveness of Genasense (oblimersen) with the May 23 announcement that the troubled antisense asset performed little better than chemotherapy alone in a targeted subset of patients with advanced melanoma.
Time To Call It Quits: Genasense Failure Marks Its End And Leaves Genta On The Ropes Again
Genta ended a decade-long effort to validate the effectiveness of Genasense (oblimersen) with the May 23 announcement that the troubled antisense asset performed little better than chemotherapy alone in a targeted subset of patients with advanced melanoma.
FDA Wants Another Trial Of Genta’s Genasense For CLL
FDA’s complete response letter requesting another trial concludes the agency’s review of an amended NDA submitted after an unsuccessful appeal of a “not approvable” letter.